US StockDetailed Quotes

Provided by Tiger Trade Technology Pte. Ltd.

OneStream, Inc.

23.61

-0.0100-0.04%

Volume:1.53M

Turnover:36.16M

Market Cap:5.78B

PE:-24.14

High:23.62

Open:23.60

Low:23.58

Close:23.62

52wk High:30.93

52wk Low:16.51

Shares:244.98M

Float Shares:220.70M

Volume Ratio:0.68

T/O Rate:0.69%

Dividend:- -

Dividend Rate:- -

EPS(TTM):-0.9780

EPS(LYR):-1.2330

ROE:-22.22%

ROA:-10.07%

PB:12.25

PE(LYR):-19.15

Loading ...

Overview Company News Filings

Avacta Announces Year-end Trading Update

Genmab Announces Topline Results for Epcoritamab (DuoBody® CD3xCD20) from Phase 3 EPCORE® DLBCL-1 Trial in Patients with Relapsed/Refractory Diffuse Large B-cell Lymphoma (DLBCL)

JPMorgan Downgrades Onestream to Underweight From Neutral, Adjusts Price Target to $24 From $23

MT Newswires Live

OneStream downgraded to Underweight from Neutral at JPMorgan

Johnson & Johnson Drug Slows Blood Cancer, Extends Survival In Pretreated Patients

Benzinga_recent_news

EXCLUSIVE: GT Biopharma Plans 2026 Trial For New Cancer Treatment

Benzinga_recent_news

OneStream downgraded to Neutral from Outperform at BNP Paribas

Press Release: Rigel Provides Business Update and 2026 Outlook

Press Release: Exelixis Announces Preliminary Fiscal Year 2025 Financial Results, Provides 2026 Financial Guidance and Outlines Key Priorities and Milestones for 2026

Zymeworks Outlines Strategic Priorities and Outlook for 2026

OneStream Inc. Chief Accounting Officer Pamela McIntyre Reports Sale of Common Shares

Ascendis Pharma Provides Business and Strategic Roadmap Update at 44th Annual J.P. Morgan Healthcare Conference

Cellectis Announces 2026 Strategy and Catalysts

Director Jonathan D. Mariner Reports Disposal of OneStream Inc. Common Shares

MEDIA-KKR to book 4.5 times return on OneStream via latest buyout - Bloomberg News

OneStream To Go Private In $24-A-Share Deal, Analysts See Limited Upside

Benzinga_recent_news

ALX Oncology Advances Separate Clinical Trials Evaluating Investigational CD47-Inhibitor Evorpacept and Novel EGFR-Targeted Antibody-Drug Conjugate ALX2004

Onestream Inc : Raymond James Cuts to Market Perform From Outperform

THOMSON REUTERS

U.S. RESEARCH ROUNDUP-Alcoa, BlackRock, Evercore

Jazz Pharmaceuticals' Drug Extends Survival Past Two Years in Advanced Stomach Cancer Trial

Benzinga_recent_news

{"basename":"","ssrTDKData":{"titleTemplate":"%s - Tiger Brokers","title":"Tiger Brokers | Global Stocks, Options & Futures Trading App","description":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","keywords":"tiger brokers,tiger trade,tiger brokers singapore,broker online,stock trading in singapore,share trading singapore,brokerage firm singapore,trading app,stock broker singapore,stock trading platforms,trading account","social":{"ogDescription":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.be62fbe1.png","ogUrl":"https://www.itiger.com/stock/OS/news"},"companyName":"Tiger Brokers"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"SGP","license":"TBSG","edition":"fundamental","symbol":"OS","isAnalysisPage":false},"__swrFallback__":{"@#url:\"https://hq.skytigris.cn/stock_info/detail/global\",params:#delay:false,,method:\"POST\",data:#items:@#symbol:\"OS\",,,,,undefined,":{"symbol":"OS","market":"US","secType":"STK","nameCN":"OneStream, Inc.","latestPrice":23.61,"timestamp":1768934041310,"preClose":23.62,"halted":0,"volume":1531775,"delay":0,"changeRate":-0.0004233700254022677,"floatShares":220698554,"shares":244977000,"eps":-0.97803,"marketStatus":"Trading","change":-0.01,"latestTime":"01-20 13:34:09 EST","open":23.6,"high":23.62,"low":23.58,"amount":36159596.858175,"amplitude":0.001693,"askPrice":23.62,"askSize":4984,"bidPrice":23.61,"bidSize":9178,"shortable":3,"etf":0,"ttmEps":-0.97803,"tradingStatus":2,"nextMarketStatus":{"tag":"Post-Mkt","tradingStatus":3,"beginTime":1768942800000},"marketStatusCode":2,"adr":0,"listingDate":1721793600000,"exchange":"NASDAQ","adjPreClose":23.62,"preHourTrading":{"tag":"盘前","latestPrice":23.59,"preClose":23.62,"latestTime":"09:29 EST","volume":22078,"amount":520578.442524,"timestamp":1768919399999,"change":-0.03,"changeRate":-0.00127,"amplitude":0.004657},"postHourTrading":{"tag":"盘后","latestPrice":23.62,"preClose":23.62,"latestTime":"17:16 EST","volume":14880,"amount":351465.3,"timestamp":1768601790236,"change":0,"changeRate":0,"amplitude":0},"volumeRatio":0.680107,"impliedVol":0.1048,"impliedVolPercentile":0.0159},"@#url:\"https://hq.skytigris.cn/stock_info/fundamental/all\",params:#delay:false,,method:\"POST\",data:#items:@#symbol:\"OS\",,,,,undefined,":{"symbol":"OS","floatShares":220698554,"roa":"-10.07%","roe":"-22.22%","lyrEps":-1.232998,"volumeRatio":0.680107,"shares":244977000,"dividePrice":0,"high":23.62,"amplitude":0.001693,"preClose":23.62,"low":23.58,"week52Low":16.51,"pbRate":"12.25","psRate":"10.14","week52High":30.93,"institutionHeld":0,"latestPrice":23.61,"committee":0.296145,"eps":-0.97803,"divideRate":0,"volume":1531775,"delay":0,"ttmEps":-0.97803,"open":23.6,"prevYearClose":18.38,"prevWeekClose":23.62,"prevMonthClose":18.38,"prevQuarterClose":18.38,"fiveDayClose":23.63,"twentyDayClose":18.18,"sixtyDayClose":17.54},"@#url:\"https://hq.skytigris.cn/fundamental/corporate_actions/details/OS\",params:#limit:5,,,undefined,":[{"market":"US","date":"2025-11-06","symbol":"OS","fiscalQuarterEnding":"2025/09","expectedEps":0.02,"name":null,"time":"Post Market","type":"earning","dateTimestamp":1762405200000,"reportTimeType":"post","actualEps":0.08},{"market":"US","date":"2025-08-07","symbol":"OS","fiscalQuarterEnding":"2025/06","expectedEps":0.01,"name":null,"time":"Post Market","type":"earning","dateTimestamp":1754539200000,"reportTimeType":"post","actualEps":0.05},{"market":"US","date":"2025-05-08","symbol":"OS","fiscalQuarterEnding":"2025/03","expectedEps":-0.03,"name":null,"time":"Post Market","type":"earning","dateTimestamp":1746676800000,"reportTimeType":"post","actualEps":0.04},{"market":"US","date":"2025-02-11","symbol":"OS","fiscalQuarterEnding":"2024/12","expectedEps":0.02,"name":null,"time":"Post Market","type":"earning","dateTimestamp":1739250000000,"reportTimeType":"post","actualEps":0.07},{"market":"US","date":"2024-11-07","symbol":"OS","fiscalQuarterEnding":"2024/09","expectedEps":0,"name":null,"time":"Post Market","type":"earning","dateTimestamp":1730955600000,"reportTimeType":"post","actualEps":-1.06}],"@#url:\"https://hq.skytigris.cn/fundamental/dividend/history\",params:#symbol:\"OS\",market:\"US\",,,undefined,":[],"@#url:\"https://hq.skytigris.cn/fundamental/estimate/recommendation\",params:#symbol:\"OS\",market:\"US\",delay:false,,,undefined,":{"strongBuy":0.1429,"buy":0.0476,"hold":0.7619,"sell":0.0476,"strongSell":0,"meanLabel":"HOLD","meanPercent":0.7619,"analysts":21,"updateTime":1768798800000},"@#url:\"https://hq.skytigris.cn/value_analysis/stock/OS\",params:#withQuantilePoint:true,period:\"5year\",factor:\"peRate\",delay:false,algorithm:1,,,undefined,":{"brief":{"id":"OS","date":"2026-01-16","current":-24.150588,"percent":0.195055,"low":-1655.61542,"twenty":-53.976775,"median":-21.667454,"eighty":-16.063653,"high":-12.620803,"avg":-227.443803,"sd":481.066298,"marketCap":4476593727},"quantilePoints":[{"date":"2024-08-02","current":-402.058638,"twenty":-402.058638,"median":-402.058638,"eighty":-402.058638,"marketCap":4348264172},{"date":"2024-08-09","current":-394.529993,"twenty":-398.004752,"median":-394.602383,"eighty":-391.489578,"marketCap":4266841869},{"date":"2024-08-16","current":-420.156344,"twenty":-402.058638,"median":-395.977809,"eighty":-394.529993,"marketCap":4543990864},{"date":"2024-08-23","current":-418.563746,"twenty":-420.156344,"median":-400.248867,"eighty":-394.674774,"marketCap":4526766915},{"date":"2024-08-30","current":-439.701867,"twenty":-427.829772,"median":-415.668113,"eighty":-395.977809,"marketCap":4755375690},{"date":"2024-09-06","current":-1412.285699,"twenty":-434.093948,"median":-420.156344,"eighty":-395.977809,"marketCap":4652069092},{"date":"2024-09-13","current":-1421.532228,"twenty":-630.517125,"median":-426.381956,"eighty":-397.599363,"marketCap":4682527160},{"date":"2024-09-20","current":-1491.611188,"twenty":-1406.835113,"median":-428.55368,"eighty":-398.352228,"marketCap":4913367253},{"date":"2024-09-27","current":-1641.015636,"twenty":-1479.542034,"median":-435.672004,"eighty":-401.33473,"marketCap":5405505506},{"date":"2024-10-04","current":-1582.129844,"twenty":-1582.616503,"median":-445.348351,"eighty":-408.313205,"marketCap":5211535706},{"date":"2024-10-11","current":-1384.546111,"twenty":-1557.991535,"median":-1361.673117,"eighty":-414.50986,"marketCap":4560694889},{"date":"2024-10-18","current":-1422.505547,"twenty":-1506.405635,"median":-1387.466067,"eighty":-417.984619,"marketCap":4685733272},{"date":"2024-10-25","current":-1513.510863,"twenty":-1501.052381,"median":-1410.582391,"eighty":-419.837824,"marketCap":4985504782},{"date":"2024-10-31","current":-1488.204572,"twenty":-1545.825049,"median":-1419.58559,"eighty":-422.588676,"marketCap":4902145859},{"date":"2024-11-08","current":-29.444986,"twenty":-1544.267739,"median":-1421.532228,"eighty":-422.588676,"marketCap":5359016876},{"date":"2024-11-15","current":-29.547337,"twenty":-1525.190689,"median":-1414.232336,"eighty":-406.749563,"marketCap":5377644907},{"date":"2024-11-22","current":-27.361909,"twenty":-1504.167001,"median":-1405.472467,"eighty":-395.977809,"marketCap":4979894851},{"date":"2024-11-29","current":-26.339693,"twenty":-1496.769778,"median":-1384.546111,"eighty":-392.705744,"marketCap":4793850470},{"date":"2024-12-06","current":-28.33551,"twenty":-1493.655158,"median":-903.058146,"eighty":-29.829328,"marketCap":5157091209},{"date":"2024-12-13","current":-28.454992,"twenty":-1490.248542,"median":-439.701867,"eighty":-28.749622,"marketCap":5178836972},{"date":"2024-12-20","current":-27.223413,"twenty":-1484.895288,"median":-431.521704,"eighty":-28.258307,"marketCap":4954688343},{"date":"2024-12-27","current":-27.048786,"twenty":-1479.834029,"median":-428.191726,"eighty":-28.004145,"marketCap":4922906075},{"date":"2025-01-03","current":-25.973452,"twenty":-1479.444702,"median":-426.381956,"eighty":-27.732022,"marketCap":4727194212},{"date":"2025-01-10","current":-24.227183,"twenty":-1479.444702,"median":-422.183287,"eighty":-27.252823,"marketCap":4409371530},{"date":"2025-01-17","current":-26.460569,"twenty":-1468.54353,"median":-415.668113,"eighty":-26.869269,"marketCap":4815850013},{"date":"2025-01-24","current":-27.894348,"twenty":-1465.818237,"median":-402.058638,"eighty":-26.861301,"marketCap":5076799163},{"date":"2025-01-31","current":-27.407231,"twenty":-1462.314289,"median":-396.991281,"eighty":-26.925021,"marketCap":4988143362},{"date":"2025-02-07","current":-27.09474,"twenty":-1459.102337,"median":-394.674774,"eighty":-26.925021,"marketCap":4931269830},{"date":"2025-02-14","current":-19.646244,"twenty":-1457.642359,"median":-390.041762,"eighty":-26.782239,"marketCap":4247537655},{"date":"2025-02-21","current":-19.437413,"twenty":-1455.695721,"median":-30.305187,"eighty":-26.72172,"marketCap":4202388031},{"date":"2025-02-28","current":-18.385222,"twenty":-1452.094441,"median":-29.520901,"eighty":-26.562732,"marketCap":3974903390},{"date":"2025-03-07","current":-18.486889,"twenty":-1446.059864,"median":-28.777108,"eighty":-26.339693,"marketCap":3996883783},{"date":"2025-03-14","current":-16.449855,"twenty":-1440.122619,"median":-28.454992,"eighty":-26.179328,"marketCap":3556475076},{"date":"2025-03-21","current":-17.921046,"twenty":-1437.981318,"median":-28.198548,"eighty":-25.317223,"marketCap":3874548031},{"date":"2025-03-28","current":-18.76981,"twenty":-1430.38943,"median":-27.986257,"eighty":-24.094834,"marketCap":4058051659},{"date":"2025-04-04","current":-16.296269,"twenty":-1422.116219,"median":-27.889753,"eighty":-20.198845,"marketCap":3523269657},{"date":"2025-04-11","current":-15.87621,"twenty":-1419.974918,"median":-27.820821,"eighty":-19.520945,"marketCap":3432452458},{"date":"2025-04-17","current":-15.802935,"twenty":-1417.346957,"median":-27.682957,"eighty":-19.180725,"marketCap":3416610370},{"date":"2025-04-25","current":-17.317281,"twenty":-1415.400319,"median":-27.425612,"eighty":-18.846182,"marketCap":3744013527},{"date":"2025-05-02","current":-17.960471,"twenty":-1411.604376,"median":-27.370467,"eighty":-18.532156,"marketCap":3883071858},{"date":"2025-05-09","current":-18.233962,"twenty":-1408.19776,"median":-27.329108,"eighty":-18.405555,"marketCap":4289685457},{"date":"2025-05-16","current":-21.240398,"twenty":-1401.871187,"median":-27.223413,"eighty":-18.515128,"marketCap":4996973579},{"date":"2025-05-23","current":-21.307828,"twenty":-1386.882076,"median":-27.071763,"eighty":-18.645114,"marketCap":5012836988},{"date":"2025-05-30","current":-20.970679,"twenty":-1384.546111,"median":-26.979854,"eighty":-18.713226,"marketCap":4933519947},{"date":"2025-06-06","current":-21.779837,"twenty":-1366.053052,"median":-26.837395,"eighty":-18.714534,"marketCap":5123880845},{"date":"2025-06-13","current":-21.083062,"twenty":-1357.293182,"median":-26.745487,"eighty":-18.76981,"marketCap":4959958960},{"date":"2025-06-20","current":-21.397734,"twenty":-630.517125,"median":-26.722672,"eighty":-18.799724,"marketCap":5033988198},{"date":"2025-06-27","current":-20.715944,"twenty":-446.043303,"median":-26.635196,"eighty":-18.835877,"marketCap":4873591516},{"date":"2025-07-03","current":-19.974216,"twenty":-441.960461,"median":-26.551186,"eighty":-18.852455,"marketCap":4699094026},{"date":"2025-07-11","current":-19.329886,"twenty":-438.862005,"median":-26.400131,"eighty":-18.891318,"marketCap":4547510347},{"date":"2025-07-18","current":-18.603142,"twenty":-435.145985,"median":-26.322706,"eighty":-18.792246,"marketCap":4376538059},{"date":"2025-07-25","current":-18.767971,"twenty":-431.217662,"median":-26.184843,"eighty":-18.769074,"marketCap":4415315279},{"date":"2025-08-01","current":-17.868906,"twenty":-429.132806,"median":-25.973452,"eighty":-18.719624,"marketCap":4203803170},{"date":"2025-08-08","current":-16.647677,"twenty":-428.119335,"median":-25.013004,"eighty":-18.618108,"marketCap":3916499222},{"date":"2025-08-15","current":-15.000942,"twenty":-427.308558,"median":-24.227183,"eighty":-18.552195,"marketCap":3687831610},{"date":"2025-08-22","current":-15.038842,"twenty":-426.26613,"median":-22.921489,"eighty":-18.339199,"marketCap":3697149022},{"date":"2025-08-29","current":-15.031262,"twenty":-424.84727,"median":-21.776091,"eighty":-18.209869,"marketCap":3695285539},{"date":"2025-09-05","current":-14.902401,"twenty":-422.588676,"median":-21.667454,"eighty":-17.977035,"marketCap":3663606339},{"date":"2025-09-12","current":-14.629519,"twenty":-419.519305,"median":-21.457672,"eighty":-17.846429,"marketCap":3596520974},{"date":"2025-09-19","current":-14.72806,"twenty":-417.405493,"median":-21.307828,"eighty":-17.519829,"marketCap":3620746244},{"date":"2025-09-26","current":-14.77354,"twenty":-413.351607,"median":-21.281605,"eighty":-17.355901,"marketCap":3631927139},{"date":"2025-10-03","current":-14.030694,"twenty":-406.749563,"median":-21.240398,"eighty":-17.207371,"marketCap":3449305866},{"date":"2025-10-10","current":-14.117865,"twenty":-400.610822,"median":-21.169222,"eighty":-16.756085,"marketCap":3470735914},{"date":"2025-10-17","current":-12.620803,"twenty":-398.265359,"median":-21.090554,"eighty":-16.357703,"marketCap":3102698146},{"date":"2025-10-24","current":-13.666851,"twenty":-397.193975,"median":-21.023124,"eighty":-16.016618,"marketCap":3359858713},{"date":"2025-10-31","current":-13.735072,"twenty":-395.977809,"median":-20.970679,"eighty":-15.832245,"marketCap":3376630054},{"date":"2025-11-07","current":-14.462758,"twenty":-395.456595,"median":-20.749659,"eighty":-15.429973,"marketCap":3555524361},{"date":"2025-11-14","current":-49.128605,"twenty":-394.616862,"median":-20.970679,"eighty":-15.543674,"marketCap":4065244662},{"date":"2025-11-21","current":-44.083947,"twenty":-393.313827,"median":-21.023124,"eighty":-15.695275,"marketCap":3647814359},{"date":"2025-11-28","current":-47.333434,"twenty":-390.910451,"median":-21.086808,"eighty":-15.767745,"marketCap":3916699644},{"date":"2025-12-05","current":-42.56146,"twenty":-321.664361,"median":-21.157984,"eighty":-15.81759,"marketCap":3521833141},{"date":"2025-12-12","current":-41.038973,"twenty":-53.555179,"median":-21.221667,"eighty":-15.87621,"marketCap":3395851924},{"date":"2025-12-19","current":-41.311658,"twenty":-51.928163,"median":-21.277859,"eighty":-15.887608,"marketCap":3418415724},{"date":"2025-12-26","current":-42.788697,"twenty":-51.673657,"median":-21.292844,"eighty":-15.933201,"marketCap":3540636308},{"date":"2026-01-02","current":-41.766131,"twenty":-50.564742,"median":-21.307828,"eighty":-15.991821,"marketCap":3456022057},{"date":"2026-01-09","current":-53.627894,"twenty":-52.309921,"median":-21.525102,"eighty":-16.02676,"marketCap":4437547364},{"date":"2026-01-16","current":-54.099771,"twenty":-53.976775,"median":-21.667454,"eighty":-16.063653,"marketCap":4476593727}],"updateTime":1768903490266},"$inf$@#url:\"https://stock-news.skytigris.cn/v2/news/list\",params:#symbols:\"OS\",pageSize:20,pageCount:1,lang_content:\"en\",edition:\"fundamental\",,,undefined,":[{"items":[{"id":"2604190551","title":"Avacta Announces Year-end Trading Update","url":"https://stock-news.laohu8.com/highlight/detail?id=2604190551","media":"GlobeNewswire","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2604190551?lang=en_us&edition=fundamental","pubTime":"2026-01-20 20:00","pubTimestamp":1768910400,"startTime":"0","endTime":"0","summary":"LONDON and PHILADELPHIA, Jan.  20, 2026  (GLOBE NEWSWIRE) -- Avacta Therapeutics (AIM: AVCT), a clinical stage biopharmaceutical company developing pre|CISION,a tumor-activated oncology delivery platf","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.globenewswire.com/news-release/2026/01/20/3221535/0/en/Avacta-Announces-Year-end-Trading-Update.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["LU0509642566.USD","BK4585","LU1487256676.USD","LU1481600234.SGD","BK4526","IE00B12V2V27.USD","TME","01698","BK4552","BK4565","BK4548","LU2463526074.USD","LU1169590202.USD","IE00BYTNYN87.SGD","BK4509","LU1023057109.AUD","LU2039709279.SGD","SG9999011746.SGD","IE00B3T34201.USD","LU1481599808.USD","LU0359202008.SGD","IE00BYQNZ168.SGD","BK4571","BK4108","BK4531","LU0456842615.SGD","BK4136","IP","BK4535","LU1169589451.USD","OS","LU0828238088.HKD","BK4097","LU0359201612.USD","BK4563","LU0269904917.USD","BK4588"],"gpt_icon":0},{"id":"2604796913","title":"Genmab Announces Topline Results for Epcoritamab (DuoBody® CD3xCD20) from Phase 3 EPCORE® DLBCL-1 Trial in Patients with Relapsed/Refractory Diffuse Large B-cell Lymphoma (DLBCL)","url":"https://stock-news.laohu8.com/highlight/detail?id=2604796913","media":"GlobeNewswire","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2604796913?lang=en_us&edition=fundamental","pubTime":"2026-01-17 02:30","pubTimestamp":1768588200,"startTime":"0","endTime":"0","summary":"Company Announcement  Based on the topline results from the EPCORE DLBCL-1 trial, Genmab will engage global regulatory authorities to discuss next steps COPENHAGEN, Denmark; January 16, 2026 – Genmab ","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.globenewswire.com/news-release/2026/01/16/3220513/0/en/Genmab-Announces-Topline-Results-for-Epcoritamab-DuoBody-CD3xCD20-from-Phase-3-EPCORE-DLBCL-1-Trial-in-Patients-with-Relapsed-Refractory-Diffuse-Large-B-cell-Lymphoma-DLBCL.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"2","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["LU0390134368.USD","LU1228905037.USD","OS","BK4585","BK4211","BK4097","BR","IE0009354923.USD","IE0034235188.USD","LU0545562505.USD","PFS","LU1228905540.USD","BK4548","BK4195","BK4588","BK4106","BK4226"],"gpt_icon":0},{"id":"2603475993","title":"JPMorgan Downgrades Onestream to Underweight From Neutral, Adjusts Price Target to $24 From $23","url":"https://stock-news.laohu8.com/highlight/detail?id=2603475993","media":"MT Newswires Live","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2603475993?lang=en_us&edition=fundamental","pubTime":"2026-01-16 20:21","pubTimestamp":1768566118,"startTime":"0","endTime":"0","summary":"Onestream (OS) has an average rating of hold and mean price target of $24.13, according to analysts polled by FactSet.(MT Newswires covers equity, commodity and economic research from major banks and ","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":["rate"],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.mtnewswires.com/","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"mtnewswires_news","symbols":["OS"],"gpt_icon":0},{"id":"2603962028","title":"OneStream downgraded to Underweight from Neutral at JPMorgan","url":"https://stock-news.laohu8.com/highlight/detail?id=2603962028","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2603962028?lang=en_us&edition=fundamental","pubTime":"2026-01-16 18:35","pubTimestamp":1768559743,"startTime":"0","endTime":"0","summary":"JPMorgan downgraded OneStream (OS) to Underweight from Neutral with a price target of $24, up from $23, citing the pending takeover by Hg. Publishe...","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/the-fly/onestream-downgraded-to-underweight-from-neutral-at-jpmorgan-thefly?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/the-fly/onestream-downgraded-to-underweight-from-neutral-at-jpmorgan-thefly?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["LU0787776722.HKD","LU0868494708.USD","LU2023250330.USD","IE00BFXG1179.USD","LU0267386448.USD","LU0149725797.USD","LU2236285917.USD","LU0211326839.USD","LU1551013342.USD","LU2505996681.GBP","IE0034235295.USD","LU2211815571.USD","LU2023250504.SGD","LU1162221912.USD","LU0943347566.SGD","BK4207","LU1366192091.USD","LU2430703095.HKD","LU1894683264.USD","LU0234572021.USD","LU0820562030.AUD","IE00BN8TJ469.HKD","LU0251132253.USD","IE00B775SV38.USD","BK4097","IE00BWXC8680.SGD","LU2264538146.SGD","LU0208291251.USD","LU2237443978.SGD","LU0964807845.USD","LU0882574139.USD","BK4504","LU0215105999.USD","OS","LU0320765646.SGD","LU1084165304.USD","LU1668664300.SGD","LU0211328371.USD","LU1119994496.HKD","LU2237443895.HKD","IE00B1XK9C88.USD","LU0976567544.SGD","LU2357305700.SGD","SG9999002232.USD","LU2054465674.USD","IE00BBT3K403.USD","LU1496350171.SGD","LU0820561818.USD","IE00BYXW3230.USD","IE00BLSP4239.USD"],"gpt_icon":0},{"id":"2603987374","title":"Johnson & Johnson Drug Slows Blood Cancer, Extends Survival In Pretreated Patients","url":"https://stock-news.laohu8.com/highlight/detail?id=2603987374","media":"Benzinga_recent_news","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2603987374?lang=en_us&edition=fundamental","pubTime":"2026-01-16 01:36","pubTimestamp":1768498560,"startTime":"0","endTime":"0","summary":"Johnson & Johnson reports Phase 3 results showing Tecvayli reduced disease progression and deaths in multiple myeloma patients, beating standard treatments with manageable side effects.","market":"us","thumbnail":"https://cdn.benzinga.com/files/images/story/2026/01/15/Exterior-Shot-Of-The-Johnson-Johnson-Cor.jpeg?optimize=medium&dpr=2&auto=webp&width=240","type":0,"news_type":0,"thumbnails":["https://cdn.benzinga.com/files/images/story/2026/01/15/Exterior-Shot-Of-The-Johnson-Johnson-Cor.jpeg?optimize=medium&dpr=2&auto=webp&width=240"],"rights":{"source":"benzinga_recent_news","url":"https://www.benzinga.com/markets/large-cap/26/01/49944767/johnson-johnson-drug-slows-blood-cancer-extends-survival-in-pretreated-patients","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.benzinga.com/markets/large-cap/26/01/49944767/johnson-johnson-drug-slows-blood-cancer-extends-survival-in-pretreated-patients","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"2","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":"benzinga_recent_news","symbols":["BK4559","IE00BKVL7J92.USD","LU2129689514.USD","IE0002141913.USD","IE00BGHQF631.EUR","LU2430703095.HKD","SG9999002224.SGD","IE00BBT3K403.USD","IE00BDGV0183.EUR","JNJ","LU1585245621.USD","LU0795875086.SGD","SG9999001440.SGD","LU2089984988.USD","LU1496350502.SGD","LU1023059063.AUD","IE00BVYPNW00.USD","IE0034235303.USD","LU0432979614.USD","LU2347655156.SGD","LU0234572021.USD","IE000M9KFDE8.USD","BK4097","LU0640476718.USD","LU2471134796.USD","IE00BFTCPJ56.SGD","LU1244550494.USD","LU2129689431.USD","LU1280957306.USD","IE00BJJMRZ35.SGD","IE00BSNM7G36.USD","LU0787776722.HKD","BK4007","LU1221951129.SGD","BK4581","LU1244550577.SGD","OS","LU1057294990.SGD","IE00B19Z3B42.SGD","LU0320765646.SGD","LU1929549753.HKD","IE0009355771.USD","LU2133065610.SGD","IE00BVYPNV92.GBP","IE00BLSP4452.SGD","PFS","BK4588","LU1894683264.USD","LU2468319806.SGD","LU0345770993.USD"],"gpt_icon":0},{"id":"2603071600","title":"EXCLUSIVE: GT Biopharma Plans 2026 Trial For New Cancer Treatment","url":"https://stock-news.laohu8.com/highlight/detail?id=2603071600","media":"Benzinga_recent_news","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2603071600?lang=en_us&edition=fundamental","pubTime":"2026-01-15 21:01","pubTimestamp":1768482060,"startTime":"0","endTime":"0","summary":"GT Biopharma submitted an IND application for GTB-5550 TriKE for solid tumors. Phase 1 trial planned for 2026.","market":"sh","thumbnail":"https://cdn.benzinga.com/files/images/story/2026/01/15/cancer.jpeg?optimize=medium&dpr=2&auto=webp&width=240","type":0,"news_type":0,"thumbnails":["https://cdn.benzinga.com/files/images/story/2026/01/15/cancer.jpeg?optimize=medium&dpr=2&auto=webp&width=240"],"rights":{"source":"benzinga_recent_news","url":"https://www.benzinga.com/news/fda/26/01/49931692/exclusive-gt-biopharma-plans-2026-trial-for-new-cancer-treatment","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.benzinga.com/news/fda/26/01/49931692/exclusive-gt-biopharma-plans-2026-trial-for-new-cancer-treatment","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":"benzinga_recent_news","symbols":["IE00BYQQ9H92.USD","LU2211817866.USD","LU2413666426.HKD","BK4533","BK4195","IE00B5TLWC47.USD","LU1093756168.USD","BK4567","GTBP","BK4588","GT","BK4139","LU2413666699.HKD","BK4121","MTD","IND","BK4211","BK4097","BK4585","IE00BFXG0V08.USD","BK4548","LU1721428933.USD","BK4119","OS","PFS","LU1093756325.SGD","LU0347712357.USD"],"gpt_icon":0},{"id":"2603070006","title":"OneStream downgraded to Neutral from Outperform at BNP Paribas","url":"https://stock-news.laohu8.com/highlight/detail?id=2603070006","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2603070006?lang=en_us&edition=fundamental","pubTime":"2026-01-15 20:50","pubTimestamp":1768481441,"startTime":"0","endTime":"0","summary":"BNP Paribas downgraded OneStream (OS) to Neutral from Outperform with a $24 price target after the company announced that it has entered into an ag...","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/the-fly/onestream-downgraded-to-neutral-from-outperform-at-bnp-paribas-thefly?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/the-fly/onestream-downgraded-to-neutral-from-outperform-at-bnp-paribas-thefly?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["BK4097","OS"],"gpt_icon":0},{"id":"2602851062","title":"Press Release: Rigel Provides Business Update and 2026 Outlook","url":"https://stock-news.laohu8.com/highlight/detail?id=2602851062","media":"Dow Jones","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2602851062?lang=en_us&edition=fundamental","pubTime":"2026-01-12 21:05","pubTimestamp":1768223100,"startTime":"0","endTime":"0","summary":"-- Preliminary fourth quarter 2025 total revenue of approximately $69.8. million, including net product sales of $65.4 million and contract. RBC-TI was achieved by 33%  of evaluable transfusion dependent. $275 to $290 million, including net product sales of $255 to $265 million,\"2025 was an excellent year for Rigel, marked by strong commercial execution with record net product sales; significant financial progress, including continued profitability and generation of $77 million in cash; and meaningful clinical advancement of R289 in lower-risk MDS, where we shared encouraging Phase 1b data,\" said Raul Rodriguez, Rigel's president and CEO. \"In 2026, we plan to continue to execute across all areas of the business -- driving sustained commercial performance, supporting our expanding clinical programs with a solid financial foundation, delivering preliminary results from the dose expansion phase of our R289 study and continuing to explore opportunities to add new products to our portfolio.","market":"sg","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://dowjonesnews.com/newdjn/logon.aspx?AL=N","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4211","RIGL","BK4109","BK4097","ORR","OS","BK4022","LU2463526074.USD","HTB","BK4139","R","ASH","BK4232"],"gpt_icon":0},{"id":"2602515003","title":"Press Release: Exelixis Announces Preliminary Fiscal Year 2025 Financial Results, Provides 2026 Financial Guidance and Outlines Key Priorities and Milestones for 2026","url":"https://stock-news.laohu8.com/highlight/detail?id=2602515003","media":"Dow Jones","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2602515003?lang=en_us&edition=fundamental","pubTime":"2026-01-12 18:37","pubTimestamp":1768214220,"startTime":"0","endTime":"0","summary":"-- Cabozantinib franchise achieves approximately $2.123 billion in preliminary U.S. net product revenues for fiscal year 2025 --. -- Fiscal year 2026 net product revenues guidance of $2.325 billion - $2.425 billion --. -- Presentation and webcast at J.P. Morgan 2026 Healthcare Conference tomorrow, Monday, January 12 at 5:15 p.m. PT / 8:15 p.m. ET --. Exelixis, Inc.  today announced its preliminary unaudited financial results for the fiscal year 2025, provided financial guidance for fiscal year 2026 and delivered an update on its business. Exelixis anticipates 2026 will be a significant year of clinical, regulatory and commercial progress as the company grows its current cabozantinib business, works toward building a potential second commercial franchise with zanzalintinib and moves its earlier stage pipeline forward. As outlined at its December 2025 R&D Day, the company seeks to leverage its diverse pipeline and key clinical collaborations to build next-generation oncology franchises t","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://dowjonesnews.com/newdjn/logon.aspx?AL=N","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["LU2065171311.SGD","BK4613","PFS","LU0456854461.SGD","BK4211","BK4554","ORR","BK4560","BK4532","BK4097","NET","LU2065171402.SGD","BK4232","BK4585","BK4195","BK4213","BK4022","BK4607","BK4588","CRC","LU2065170008.USD","BK4548","OS","BK4139","RCC","LU2065169927.USD","LU0266512127.USD","EXEL","R","LU2286300806.USD","BK4116"],"gpt_icon":0},{"id":"2602634505","title":"Zymeworks Outlines Strategic Priorities and Outlook for 2026","url":"https://stock-news.laohu8.com/highlight/detail?id=2602634505","media":"GlobeNewswire","labels":["corporation"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2602634505?lang=en_us&edition=fundamental","pubTime":"2026-01-12 07:00","pubTimestamp":1768172400,"startTime":"0","endTime":"0","summary":"Positive Phase 3 HERIZON-GEA-01 results for Ziihera (zanidatamab-hrii) in first-line HER2-positive (HER2+)gastroesophageal adenocarcinoma (GEA) presented at ASCO GI Up to $440.0 million in milestone p","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.globenewswire.com/news-release/2026/01/11/3216504/0/en/Zymeworks-Outlines-Strategic-Priorities-and-Outlook-for-2026.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"corporation","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4161","LU0075056555.USD","JF","PFS","ADC","LU0345780521.USD","LU0368265764.SGD","BK4195","LU0300736492.USD","LU0630314457.HKD","LU0654597011.USD","LU0612318385.USD","B","LU0345780950.USD","LU0055631609.USD","LU0788108826.HKD","LU1023059493.AUD","OS","LU0498741890.SGD","LU0724618789.USD","PT","BK4166","LU0788109121.HKD","BK4080","LU0498741114.HKD","BK4211","SG9999001143.SGD","LU0345780281.USD","BK4017","LU0612318971.USD","IND","LU0330918003.SGD","LU0496367417.USD","LU1430597077.USD","LU0300736062.USD","BK4231","SG9999002521.SGD","LU0345781412.USD","BK4097"],"gpt_icon":0},{"id":"2602024603","title":"OneStream Inc. Chief Accounting Officer Pamela McIntyre Reports Sale of Common Shares","url":"https://stock-news.laohu8.com/highlight/detail?id=2602024603","media":"Reuters","labels":["shareholding","insiderTrades","express"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2602024603?lang=en_us&edition=fundamental","pubTime":"2026-01-10 07:19","pubTimestamp":1768000747,"startTime":"0","endTime":"0","summary":"Pamela McIntyre, Chief Accounting Officer of OneStream Inc., reported a disposal of common shares of OneStream Inc. The full filing can be accessed through the link below.Disclaimer: This news brief was created by Public Technologies  using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. OneStream Inc. published the original content used to generate this news brief via EDGAR, the Electronic Data Gathering, Analysis, and Retrieval system operated by the U.S. Securities and Exchange Commission , on January 09, 2026, and is solely responsible for the information contained therein.","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260109:nNDL29n82W:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":"OneStream Inc. Chief Accounting Officer Pamela McIntyre Reports Sale of Common Shares","news_tag":"shareholding,insiderTrades,express","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["OS","BK4097"],"gpt_icon":0},{"id":"2602302197","title":"Ascendis Pharma Provides Business and Strategic Roadmap Update at 44th Annual J.P. Morgan Healthcare Conference","url":"https://stock-news.laohu8.com/highlight/detail?id=2602302197","media":"GlobeNewswire","labels":["conferences"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2602302197?lang=en_us&edition=fundamental","pubTime":"2026-01-10 07:01","pubTimestamp":1767999660,"startTime":"0","endTime":"0","summary":"- Rapidly transforming into a leading global biopharma companyCOPENHAGEN, Denmark, Jan.  09, 2026  (GLOBE NEWSWIRE) -- Ascendis Pharma A/S (Nasdaq: ASND) today provided a business and strategic roadma","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.globenewswire.com/news-release/2026/01/09/3216381/0/en/Ascendis-Pharma-Provides-Business-and-Strategic-Roadmap-Update-at-44th-Annual-J-P-Morgan-Healthcare-Conference.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"conferences","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["LU1548497426.USD","LU2089283258.USD","BK4137","LABU","XBI","LU2111349929.HKD","BK4125","XLV","LU2347655156.SGD","PROC","BK4007","LU0795875086.SGD","LU1074936037.SGD","LU2028103732.USD","IE00BZ1G4Q59.USD","BK4534","LU1791710400.SGD","BK4215","LU0234570918.USD","LU0314104364.USD","LU1244550577.SGD","MAA","LU1732800096.USD","LU0557290698.USD","LU0912757837.SGD","BK4585","BK4581","LU1989772923.USD","LU2023251221.USD","LU2133065610.SGD","BK4588","LU1244550494.USD","LU0882574139.USD","BK4504","LU0029874061.USD","OS","LU0528227936.USD","EMA","BK4081","LU0795875169.SGD","LU1989772840.SGD","LU1244550221.USD","LU0098860793.USD","BK4127","LU1791710582.SGD","HCSG","SGA","LU0971096721.USD","LU1720051108.HKD","LU0106261372.USD"],"gpt_icon":0},{"id":"2602139483","title":"Cellectis Announces 2026 Strategy and Catalysts","url":"https://stock-news.laohu8.com/highlight/detail?id=2602139483","media":"GlobeNewswire","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2602139483?lang=en_us&edition=fundamental","pubTime":"2026-01-09 05:30","pubTimestamp":1767907800,"startTime":"0","endTime":"0","summary":"NEW YORK, Jan.  08, 2026  (GLOBE NEWSWIRE) -- Cellectis (the “Company”) (Euronext Growth: ALCLS - NASDAQ: CLLS), a clinical-stage biotechnology company using its pioneering gene editing platform to de","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.globenewswire.com/news-release/2026/01/08/3215815/0/en/Cellectis-Announces-2026-Strategy-and-Catalysts.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["OS","BK4139","BK4097","BK4505","ASH","ORR","LU2463526074.USD","TIL","BK4109","CLLS"],"gpt_icon":0},{"id":"2602031876","title":"Director Jonathan D. Mariner Reports Disposal of OneStream Inc. Common Shares","url":"https://stock-news.laohu8.com/highlight/detail?id=2602031876","media":"Reuters","labels":["insiderTrades","express"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2602031876?lang=en_us&edition=fundamental","pubTime":"2026-01-09 05:22","pubTimestamp":1767907368,"startTime":"0","endTime":"0","summary":"Jonathan D. Mariner, Director at OneStream Inc., has reported the disposal of common shares of the company. The full filing can be accessed through the link below.Disclaimer: This news brief was created by Public Technologies  using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. OneStream Inc. published the original content used to generate this news brief via EDGAR, the Electronic Data Gathering, Analysis, and Retrieval system operated by the U.S. Securities and Exchange Commission , on January 08, 2026, and is solely responsible for the information contained therein.","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260108:nNDL7k2x2F:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":"Director Jonathan D. Mariner Reports Disposal of OneStream Inc. Common Shares","news_tag":"insiderTrades,express","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["OS","BK4097"],"gpt_icon":0},{"id":"2602390209","title":"MEDIA-KKR to book 4.5 times return on OneStream via latest buyout - Bloomberg News","url":"https://stock-news.laohu8.com/highlight/detail?id=2602390209","media":"Reuters","labels":["shareholding","merge"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2602390209?lang=en_us&edition=fundamental","pubTime":"2026-01-09 04:46","pubTimestamp":1767905184,"startTime":"0","endTime":"0","summary":"MEDIA-KKR to book 4.5 times return on OneStream via latest buyout - Bloomberg News -- Source link: https://tinyurl.com/2y67x2tm-- Note: Reuters has not verified this story and does not vouch for its accuracy ((globalnewsmonitoring@thomsonreuters.com))","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260108:nL4N3Y91GC:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"2","news_top_title":null,"news_tag":"shareholding,merge","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["LU1201861249.SGD","BK4585","LU0314104364.USD","IE00BGHQF748.EUR","LU1935042215.USD","LU1935042991.SGD","BK4588","OS","LU0980610538.SGD","LU1935043536.SGD","LU1668664300.SGD","LU0106831901.USD","IE00B3QW5Z07.USD","BK4135","IE00B64PRP62.GBP","LU1791807156.HKD","LU1935043023.USD","LU0130102774.USD","LU0648001328.SGD","BK4097","LU1935042488.USD","KKR"],"gpt_icon":0},{"id":"2601362264","title":"OneStream To Go Private In $24-A-Share Deal, Analysts See Limited Upside","url":"https://stock-news.laohu8.com/highlight/detail?id=2601362264","media":"Benzinga_recent_news","labels":["corporation"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2601362264?lang=en_us&edition=fundamental","pubTime":"2026-01-08 21:31","pubTimestamp":1767879060,"startTime":"0","endTime":"0","summary":"OneStream receives an offer from Hg Capital for $24 per share. Analysts from Needham, Rosenblatt and BTIG provide insights.","market":"hk","thumbnail":"https://cdn.benzinga.com/files/images/story/2026/01/08/Konskie--Poland---February-22--2025-Ones.jpeg?optimize=medium&dpr=2&auto=webp&width=240","type":0,"news_type":0,"thumbnails":["https://cdn.benzinga.com/files/images/story/2026/01/08/Konskie--Poland---February-22--2025-Ones.jpeg?optimize=medium&dpr=2&auto=webp&width=240"],"rights":{"source":"benzinga_recent_news","url":"https://www.benzinga.com/analyst-stock-ratings/analyst-color/26/01/49781464/onestream-analysts-shrug-downgrade-on-pending-acquisition","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.benzinga.com/analyst-stock-ratings/analyst-color/26/01/49781464/onestream-analysts-shrug-downgrade-on-pending-acquisition","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"corporation","news_rank":0,"length":0,"strategy_id":0,"source":"benzinga_recent_news","symbols":["LU1815336091.USD","BK4097","LU0566484027.USD","LU1935042991.SGD","LU1559883803.SGD","LU0757428866.USD","LU0648001328.SGD","OS","LU0314104364.USD","BK4585","BL","BK4135","LU1935042215.USD","LU0130102774.USD","LU1791807156.HKD","KKR","WK","IE00B3QW5Z07.USD","LU1201861249.SGD","BK4588","LU1935043536.SGD","LU0980610538.SGD","LU1935043023.USD","BK4023","LU1935042488.USD","LU1668664300.SGD","IE00BGHQF748.EUR","IE00B64PRP62.GBP","LU0106831901.USD"],"gpt_icon":0},{"id":"2601236783","title":"ALX Oncology Advances Separate Clinical Trials Evaluating Investigational CD47-Inhibitor Evorpacept and Novel EGFR-Targeted Antibody-Drug Conjugate ALX2004","url":"https://stock-news.laohu8.com/highlight/detail?id=2601236783","media":"GlobeNewswire","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2601236783?lang=en_us&edition=fundamental","pubTime":"2026-01-08 21:30","pubTimestamp":1767879000,"startTime":"0","endTime":"0","summary":"- First patient dosed in Phase 2 ASPEN-09-Breast trial evaluating evorpacept in combination with trastuzumab and physician’s choice of chemotherapy in HER2-positive metastatic breast cancer; interim a","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.globenewswire.com/news-release/2026/01/08/3215379/0/en/ALX-Oncology-Advances-Separate-Clinical-Trials-Evaluating-Investigational-CD47-Inhibitor-Evorpacept-and-Novel-EGFR-Targeted-Antibody-Drug-Conjugate-ALX2004.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4195","BK4211","OS","BK4097","ORR","BK4231","CRC","BK4213","BK4080","LU0456854461.SGD","PFS","ALX","ADC","LU0266512127.USD"],"gpt_icon":0},{"id":"2601352432","title":"Onestream Inc : Raymond James Cuts to Market Perform From Outperform","url":"https://stock-news.laohu8.com/highlight/detail?id=2601352432","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2601352432?lang=en_us&edition=fundamental","pubTime":"2026-01-08 17:27","pubTimestamp":1767864467,"startTime":"0","endTime":"0","summary":null,"market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260108:nFWN3Y90GT:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["BK4097","OS"],"gpt_icon":0},{"id":"2601355386","title":"U.S. RESEARCH ROUNDUP-Alcoa, BlackRock, Evercore","url":"https://stock-news.laohu8.com/highlight/detail?id=2601355386","media":"Reuters","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2601355386?lang=en_us&edition=fundamental","pubTime":"2026-01-08 15:12","pubTimestamp":1767856359,"startTime":"0","endTime":"0","summary":"U.S. RESEARCH ROUNDUP-Alcoa, BlackRock, EvercoreJan 8 (Reuters) - Wall Street securities analysts revised their ratings and price targets on several U.S.-listed companies, including Alcoa, BlackRock...","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260108:nL4N3Y90FF:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BLK","GMED","BX","APD","CACC","BK4534","LU2272731600.USD","BK4139","EPAM","APO","LU0130103400.USD","AZTA","EXE","HLI","IVZ","HALO","BK4533","LU1804176565.USD","GLUE","GM","KKR","SG9999002224.SGD","PJT","SG9999002232.USD","MSM","JLL","OS","BWA","F","ARES","FHI","CG","FCX","HLNE","CTSH","PCTY","PAYC","IE","AA","FIGR","INTU","RIVN","DNA","AMG","COMP","LU0971096721.USD","GDYN","EVR","CBRE","ACI"],"gpt_icon":1},{"id":"2601383883","title":"Jazz Pharmaceuticals' Drug Extends Survival Past Two Years in Advanced Stomach Cancer Trial","url":"https://stock-news.laohu8.com/highlight/detail?id=2601383883","media":"Benzinga_recent_news","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2601383883?lang=en_us&edition=fundamental","pubTime":"2026-01-08 02:12","pubTimestamp":1767809520,"startTime":"0","endTime":"0","summary":"Jazz Pharmaceuticals reported Phase 3 trial results showing Ziihera helped patients with advanced HER2-positive stomach cancer live longer, with some treatments pushing survival beyond two years.","market":"sh","thumbnail":"https://cdn.benzinga.com/files/images/story/2026/01/07/cancer.jpeg?optimize=medium&dpr=2&auto=webp&width=240","type":0,"news_type":0,"thumbnails":["https://cdn.benzinga.com/files/images/story/2026/01/07/cancer.jpeg?optimize=medium&dpr=2&auto=webp&width=240"],"rights":{"source":"benzinga_recent_news","url":"https://www.benzinga.com/news/financing/26/01/49763409/jazz-pharmaceuticals-drug-extends-survival-past-two-years-in-advanced-stomach-cancer-trial","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.benzinga.com/news/financing/26/01/49763409/jazz-pharmaceuticals-drug-extends-survival-past-two-years-in-advanced-stomach-cancer-trial","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"2","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":"benzinga_recent_news","symbols":["IE00B66KJ199.SGD","BK4585","IE00BN0W2W23.USD","BK4532","ONC","JAZZ","LU0109394709.USD","BK4097","PFS","LU0823416689.USD","IE00BN0W2T93.GBP","IE00B7SZL793.SGD","BK4139","BK4533","OS","LU1815336091.USD","BK4157","BK4526","IE0031619046.USD","LU0154245673.USD","LU0889565916.HKD","BK4007","ZYME","IE00B19Z4B17.USD","BK4211","LU0154245756.USD","AEIS","LU0320765992.SGD","LU0757428866.USD","IE00BN0W2V16.EUR","BK4195"],"gpt_icon":0}],"pageSize":20,"totalPage":10,"pageCount":1,"totalSize":200,"code":"91000000","status":"200"}]}}